ProCE Banner Activity

My Perspective on the Use of PARP Inhibition in Pancreatic Cancer Treatment

Clinical Thought
Now that olaparib is approved in the EU, how will your treatment of patients with pancreatic cancer change?

Released: October 30, 2020

Expiration: October 29, 2021

Share

Faculty

Dirk Arnold

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Dirk Arnold, MD, PhD

Director
Asklepios Tumorzentrum Hamburg
Department of Oncology
AK Altona
Hamburg, Germany

Dirk Arnold, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, MSD, Pierre Fabre, and Roche; funds for research support from AstraZeneca, Bristol-Myers Squibb, and Pierre Fabre; fees for non-CME/CE services from Amgen, AstraZeneca, Bristol-Myers Squibb, MSD, Pierre Fabre, and Roche; and other financial or material support from AstraZeneca.